.jetcityimage/iStock Editorial using Getty Images Morgan Stanley has selected Eli Lilly (NYSE: LLY) as its own best biopharma choice for 2025 and also ranked another nine titles in the area as over weight. The investment banking company said in a note that it remains to believe “diabesity is actually readied to come to be.